论文部分内容阅读
目的探讨胸苷酸合成酶基因表达与晚期肺腺癌培美曲塞化疗疗效的关系。方法40例晚期肺腺癌患者接受培美曲塞-顺铂方案化疗,根据胸苷酸合成酶基因表达水平分为低表达组(12例)和高表达组(28例),实时荧光定量PCR检测外周血胸苷酸合成酶mRNA的表达。结果低表达组化疗缓解率显著高于高表达组(58.3%vs.21.4%)(P<0.05);低表达组中位无进展生存时间显著长于高表达组(5.7个月vs.3.6个月)(P<0.05)。结论胸苷酸合成酶mRNA可作为培美曲塞治疗晚期肺腺癌的疗效预测指标。
Objective To investigate the relationship between thymidylate synthase gene expression and the efficacy of pemetrexed chemotherapy for advanced lung adenocarcinoma. Methods Forty patients with advanced lung adenocarcinoma undergoing chemotherapy with pemetrexed - cisplatin were divided into low expression group (n = 12) and high expression group (n = 28) according to the expression of thymidylate synthase gene. Real - time fluorescence quantitative PCR Detection of peripheral blood thymidylate synthase mRNA expression. Results The response rate of low expression group was significantly higher than that of high expression group (58.3% vs.21.4%, P <0.05), and the median progression-free survival time of low expression group was significantly longer than that of high expression group (5.7 months vs.3.6 months ) (P <0.05). Conclusion Thymidylate synthase mRNA can be used as a predictive value of pemetrexed in the treatment of advanced lung adenocarcinoma.